Centre Francois Baclesse

The Oncology-Neurology department in Caen is running a broad portfolio focused on cancer, with strong activity in breast cancer, lung cancer, ovarian cancer, prostate cancer, and head and neck cancers. Many studies are designed to test new treatment strategies, compare them with current care, and improve outcomes for people with advanced or hard-to-treat disease.

• Research in neoplasms includes studies of metastatic, recurrent, and treatment-resistant cancers across multiple tumor types.
• Trials frequently focus on evaluating the effectiveness of new immunotherapy, targeted therapy, and combination treatment approaches.
• Several studies aim to improve disease control after surgery or standard treatment, especially in breast, ovarian, and endometrial cancer.
• Work in digestive system diseases also appears through trials in gastroesophageal adenocarcinoma and related cancers.

Overall, the site shows a strong emphasis on advancing care for patients with complex solid tumors, including efforts to refine treatment selection and improve survival in Centre Francois Baclesse.

A major part of the research portfolio is dedicated to breast cancer, especially ER-positive, HER2-negative, HER2-positive, and triple negative breast cancer. These studies explore ways to prevent recurrence, treat metastatic disease, and improve outcomes after surgery and standard therapy.

• Studies in early breast cancer are looking at ways to reduce the chance of relapse after initial treatment.
• Research in metastatic breast cancer includes testing new combinations for difficult-to-treat or resistant disease.
• Trials also address ESR1 and HER2 alterations to help match treatment to tumor biology.
• Some projects focus on patients with residual disease after neoadjuvant therapy, aiming to improve long-term disease control.

These efforts reflect a strong interest in personalized treatment strategies for breast cancer across early and advanced stages.

The site is also active in non-small cell lung cancer, small cell lung carcinoma, and other thoracic tumors. The research is centered on testing new targeted and immune-based treatments, especially for advanced disease and tumors with specific molecular features.

• Trials include patients with advanced NSCLC, metastatic squamous NSCLC, and mutation-defined lung cancers.
• Several studies evaluate combinations intended to improve tumor response and extend survival.
• Research also includes neuroendocrine lung carcinoma and tumors expressing markers such as DLL3.
• Some studies aim to improve treatment options for patients whose disease has limited standard choices.

This area highlights a strong focus on precision oncology and next-generation treatment approaches for lung cancer.

Another important field at Centre Francois Baclesse is gynecologic oncology, with studies in ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, and primary peritoneal carcinoma. The trials aim to improve both first-line and later-line treatment outcomes in these diseases.

• Research includes strategies for advanced ovarian and peritoneal cancers, where recurrence remains a major challenge.
• Studies in endometrial cancer are testing ways to improve survival after surgery and in advanced disease.
• Some projects examine whether new treatment combinations can better control cervical and other gynecologic tumors.
• There is also interest in postoperative treatment and maintenance approaches to delay progression.

These trials are aimed at improving long-term outcomes for women with aggressive or recurrent gynecologic cancers.

The remaining studies cover a wide range of solid tumors, including prostate cancer, renal cell carcinoma, bladder cancer, melanoma, esophageal cancer, and head and neck squamous cell carcinoma. Many of these trials are investigating targeted therapy, immunotherapy, or biomarker-driven treatment selection.

• Research in prostate cancer includes advanced and metastatic disease, with attention to improving disease control and symptom management.
• Studies in renal and urothelial cancers focus on patients with advanced or hard-to-treat tumors.
• Head and neck cancer trials are evaluating new combinations to improve response and reduce recurrence.
• Some projects address melanoma, solid tumors with specific molecular alterations, and rare cancers such as adenoid cystic carcinoma.

Across these areas, the research aims to broaden treatment options and better tailor care to tumor biology and disease stage.

In addition to tumor-directed studies, the site conducts research on cancer-related symptoms and neurologic complications, including chemotherapy-induced peripheral neuropathy and glioblastoma. This reflects an interest in both improving quality of life and refining treatment for brain tumors.

• Studies on chemotherapy-induced peripheral neuropathy are evaluating better ways to relieve pain and nerve-related symptoms.
• Research in glioblastoma is focused on improving survival in one of the most aggressive brain cancers.
• These projects connect oncology with supportive care and neuro-oncology expertise.

This mix of symptom management and brain tumor research adds an important clinical dimension to the site’s overall portfolio.